Telemedicine trial results to be presented at ACC 24

TEL AVIV, Israel & ZURICH & NEW YORK – SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN), a company specializing in advanced personal telemedicine solutions, has announced that the TELE-ACS clinical trial results will be showcased at the American College of Cardiology’s 24th Annual Scientific Session & Expo (ACC 24). The trial, a collaboration with Imperial College London, examines the effectiveness of remote cardiovascular patient assessment post-acute coronary syndrome using SHL’s SmartHeart® technology.

The presentation, scheduled for April 6, 2024, will reveal the full findings of the TELE-ACS trial, a study that could mark a significant advancement in telemedicine for cardiovascular care. The trial focused on high-risk patients following an acute coronary syndrome and utilized SHL’s SmartHeart® 12-lead ECG technology for at-home monitoring.

Erez Nachtomy, CEO of SHL Telemedicine, expressed pride in the trial’s selection for ACC 24, recognizing it as a testament to the diligent efforts of the team at Imperial College London. The results, which are currently embargoed, will be shared with the global cardiology community during the conference.

SHL Telemedicine, listed on both the SIX Swiss Exchange and the Nasdaq Stock Exchange, provides telemedicine systems and medical call center services, concentrating on cardiovascular and related diseases. The company offers its services and devices to subscribers through telephonic and internet communication technologies.

The announcement is based on a press release statement.

InvestingPro Insights

As SHL Telemedicine Ltd. (NASDAQ: SHLTN) prepares to reveal the TELE-ACS clinical trial results, investors and stakeholders are closely observing the company’s financial health and market performance. According to the latest data from InvestingPro, SHL Telemedicine holds a market capitalization of 110.19 million USD, indicating its size and significance in the telemedicine industry. Despite recent challenges, as the stock has fared poorly over the last month with a 16.55% drop, SHL Telemedicine’s liquid assets exceed its short-term obligations, which may provide some financial stability for the company.

InvestingPro Tips suggest that SHL Telemedicine is trading near its 52-week low and operates with a moderate level of debt, which could present a buying opportunity for investors who believe in the company’s long-term prospects. Notably, the firm has not been profitable over the last twelve months, and it does not pay a dividend to shareholders, indicating that potential investors should have a tolerance for risk and a focus on growth potential.

For those interested in a deeper analysis, InvestingPro+ offers additional tips on SHL Telemedicine, and with the current special New Year sale, subscriptions are now available at up to 50% off. To further enhance this offer, use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.